Ignite Creation Date:
2025-12-24 @ 7:01 PM
Ignite Modification Date:
2025-12-25 @ 4:35 PM
Study NCT ID:
NCT00584857
Status:
COMPLETED
Last Update Posted:
2017-01-27
First Post:
2007-12-21
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
A Phase II Study of Therapy With Paclitaxel, Carboplatin and Megesterol Acetate for the Management of Uterine Cancer
Sponsor:
University of Alabama at Birmingham
Organization:
Study Overview
Official Title:
A Phase II Study of Combination Therapy With Paclitaxel, Carboplatin and Megesterol Acetate for the Management of Advanced Stage or Recurrent Carcinoma of the Endometrium
Status:
COMPLETED
Status Verified Date:
2017-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a study to determine the optimal treatment for patients with advanced stage or recurrent endometrial cancer. Traditionally, patients have been treated with either hormonal therapies (megesterol) or chemotherapy (paclitaxel and carboplatin). This study investigates the effectiveness of the combination of hormonal therapy and chemotherapy. This study also will examine the side-effects associated with these drugs and the quality of life of patients on combination therapy.
Detailed Description:
Endometrial cancer is the most common gynecologic malignancy with 40,100 new cases diagnosed and 6,800 deaths attributable to this malignancy in 2003. Most patients diagnosed with endometrial cancer have early stage disease that is amenable to treatment with hysterectomy and bilateral salpingo-oophorectomy with excellent clinical outcomes. Surgical staging has improved accuracy over clinical staging for defining a low risk population of patients who have favorable long-term outcomes with surgery alone. However, approximately 15% of patients will have evidence of Stage III or IV disease at the time of initial diagnosis and 15% of surgical Stage I/II patients will have recurrent disease. Radiation therapy will be effective in patients with disease confined to the pelvis; however, patients with metastatic disease will require more systemic therapy in order to control disease.
Multiple chemotherapeutic agents including cisplatin, doxorubicin HCL, paclitaxel, carboplatin, and oral etoposide, alone and in combination, have been studied for persistent, advanced or recurrent endometrial cancer. A phase III study by the Gynecologic Oncology Group (GOG) compared doxorubicin with and without cisplatin (GOG 107) for patients with advanced or recurrent endometrial cancer. A higher response rate (45% vs. 27%) was noted for combination therapy and has been considered by many to be the standard chemotherapy regimen for treatment of patients with advanced endometrial cancer. However, clinical trials have continued to define the optimal chemotherapy regimen for this disease. Recently, the use of whole abdominal radiation therapy in the adjuvant setting for advanced endometrial cancer was demonstrated to be inferior to the combination of cisplatin and doxorubicin. The predicted 2-year survival of 70% for patients receiving the chemotherapeutic regimen was superior to patients that received radiation therapy (59%)(p\<0.01).
Hormonal and cytotoxic chemotherapy agents are utilized in patients with metastatic or recurrent disease not amenable to radiation therapy. Hormonal agents have been used in this disease process since it has been demonstrated to be a hormonal responsive tumor. Notably, a correlation between histologic grade and the presence or absence of hormonal receptors has been noted, with well differentiated tumors more likely to express hormone receptors than those with poor histology. Furthermore, the presence of estrogen receptors (ER) and progesterone receptors (PR) varies with tumor histology. ER has been reported to be present between 70% and 87% of endometrioid adenocarcinoma and 0 and 24% in UPSC; while, PR has ranged from 67% to 91% in endometrioid tumors and 0 and 19% in UPSC.
Various progestins have been investigated including Megace (megesterol acetate) and Provera (medroxyprogesterone acetate) for the treatment of endometrial cancer. These agents are generally well tolerated and have been reported to have response rates of 15-30% with long-term complete responses not uncommonly experienced. Furthermore, median survival in patients treated with progestins ranges from 9 to 20 months.
As paclitaxel has been noted to be active in ovarian cancer and other malignancies, it seems reasonable to evaluate its utility for endometrial cancer. Accordingly, single agent paclitaxel was administered to 30 chemotherapy naïve patients with advanced or recurrent endometrial cancer. The overall response rate was 36% when patients received a 24-hour infusion of paclitaxel. Furthermore, paclitaxel given as a 3-hour infusion demonstrated a response between 27 to 37% in patients that had failed prior chemotherapy.
Paclitaxel has been combined with platinum compounds, primarily cisplatin in several studies. A phase II study that combined paclitaxel 175 mg/m2 as a 3-hour infusion with cisplatin 75 mg/m2 reported a 67% response rate. There were seven complete responses and nine partial responses with an 18 month median overall survival. An additional phase II study evaluated the efficacy of combining paclitaxel and carboplatin in both primary advanced and recurrent non-papillary and papillary tumors following radiation. The response rate was 78% in patients with primary advanced non-papillary tumors with a median disease-free survival of 23 months, with the median overall survival not being reached at the time of publication. Furthermore, patients with recurrent endometrial cancer had a response rate of 56%, with a median overall survival of 15 months.
A phase I study by the GOG combined paclitaxel, cisplatin, and doxorubicin with or without granulocyte colony-stimulating factor. A 46% response rate with this regimen determined the optimal dosing of the agents and led to a phase III GOG study (GOG 177). GOG 177 demonstrated the combination of paclitaxel, doxorubicin and cisplatin to have higher response rates (57% vs. 33%) over the combination of doxorubicin and cisplatin, but the three drug combination was associated with more toxicity and 12-month overall survival (58% vs. 50%) was similar. Furthermore, more Grade 3 and 4 toxicity was experienced by patients that received the three drug combination, although this was not statistically significant. Accordingly, a phase III trial comparing the paclitaxel, doxorubicin, and cisplatin regimen to a more tolerable regimen of paclitaxel and carboplatin is planned by the GOG, based on equivalency studies in ovarian cancer patients where carboplatin was substituted for cisplatin and demonstrated easier administration with equal efficacy and less toxicity.
The combination of hormonal agents with cytotoxic chemotherapy has also been investigated. These studies utilized various combinations of non-taxane based cytotoxic chemotherapy in addition to megesterol or medroxyprogesterone acetate. Patients had response rates that varied from 33% to 60%, with the combination cyclophosphamide, doxorubicin, cisplatin and megesterol producing the greatest response rate. Additionally, Pinelli et al. reported a 56% complete or partial response rate in a group of patients treated with carboplatin and sequential hormonal therapy with megesterol and tamoxifen. These studies suggest that sequential administration of hormonal therapy with chemotherapy has no detrimental effects on patients, and may be beneficial as hormonal therapy is generally less toxic than chemotherapy. Based on known tolerability and efficacy, investigating the combination of megesterol acetate with paclitaxel and carboplatin chemotherapy appears to be a reasonable option in the setting of advanced or recurrent endometrial cancer.
Accordingly, this phase II study will evaluate the combination of paclitaxel, carboplatin and megesterol acetate for the treatment of advanced or recurrent adenocarcinoma of the endometrium.
Multiple chemotherapeutic agents including cisplatin, doxorubicin HCL, paclitaxel, carboplatin, and oral etoposide, alone and in combination, have been studied for persistent, advanced or recurrent endometrial cancer. A phase III study by the Gynecologic Oncology Group (GOG) compared doxorubicin with and without cisplatin (GOG 107) for patients with advanced or recurrent endometrial cancer. A higher response rate (45% vs. 27%) was noted for combination therapy and has been considered by many to be the standard chemotherapy regimen for treatment of patients with advanced endometrial cancer. However, clinical trials have continued to define the optimal chemotherapy regimen for this disease. Recently, the use of whole abdominal radiation therapy in the adjuvant setting for advanced endometrial cancer was demonstrated to be inferior to the combination of cisplatin and doxorubicin. The predicted 2-year survival of 70% for patients receiving the chemotherapeutic regimen was superior to patients that received radiation therapy (59%)(p\<0.01).
Hormonal and cytotoxic chemotherapy agents are utilized in patients with metastatic or recurrent disease not amenable to radiation therapy. Hormonal agents have been used in this disease process since it has been demonstrated to be a hormonal responsive tumor. Notably, a correlation between histologic grade and the presence or absence of hormonal receptors has been noted, with well differentiated tumors more likely to express hormone receptors than those with poor histology. Furthermore, the presence of estrogen receptors (ER) and progesterone receptors (PR) varies with tumor histology. ER has been reported to be present between 70% and 87% of endometrioid adenocarcinoma and 0 and 24% in UPSC; while, PR has ranged from 67% to 91% in endometrioid tumors and 0 and 19% in UPSC.
Various progestins have been investigated including Megace (megesterol acetate) and Provera (medroxyprogesterone acetate) for the treatment of endometrial cancer. These agents are generally well tolerated and have been reported to have response rates of 15-30% with long-term complete responses not uncommonly experienced. Furthermore, median survival in patients treated with progestins ranges from 9 to 20 months.
As paclitaxel has been noted to be active in ovarian cancer and other malignancies, it seems reasonable to evaluate its utility for endometrial cancer. Accordingly, single agent paclitaxel was administered to 30 chemotherapy naïve patients with advanced or recurrent endometrial cancer. The overall response rate was 36% when patients received a 24-hour infusion of paclitaxel. Furthermore, paclitaxel given as a 3-hour infusion demonstrated a response between 27 to 37% in patients that had failed prior chemotherapy.
Paclitaxel has been combined with platinum compounds, primarily cisplatin in several studies. A phase II study that combined paclitaxel 175 mg/m2 as a 3-hour infusion with cisplatin 75 mg/m2 reported a 67% response rate. There were seven complete responses and nine partial responses with an 18 month median overall survival. An additional phase II study evaluated the efficacy of combining paclitaxel and carboplatin in both primary advanced and recurrent non-papillary and papillary tumors following radiation. The response rate was 78% in patients with primary advanced non-papillary tumors with a median disease-free survival of 23 months, with the median overall survival not being reached at the time of publication. Furthermore, patients with recurrent endometrial cancer had a response rate of 56%, with a median overall survival of 15 months.
A phase I study by the GOG combined paclitaxel, cisplatin, and doxorubicin with or without granulocyte colony-stimulating factor. A 46% response rate with this regimen determined the optimal dosing of the agents and led to a phase III GOG study (GOG 177). GOG 177 demonstrated the combination of paclitaxel, doxorubicin and cisplatin to have higher response rates (57% vs. 33%) over the combination of doxorubicin and cisplatin, but the three drug combination was associated with more toxicity and 12-month overall survival (58% vs. 50%) was similar. Furthermore, more Grade 3 and 4 toxicity was experienced by patients that received the three drug combination, although this was not statistically significant. Accordingly, a phase III trial comparing the paclitaxel, doxorubicin, and cisplatin regimen to a more tolerable regimen of paclitaxel and carboplatin is planned by the GOG, based on equivalency studies in ovarian cancer patients where carboplatin was substituted for cisplatin and demonstrated easier administration with equal efficacy and less toxicity.
The combination of hormonal agents with cytotoxic chemotherapy has also been investigated. These studies utilized various combinations of non-taxane based cytotoxic chemotherapy in addition to megesterol or medroxyprogesterone acetate. Patients had response rates that varied from 33% to 60%, with the combination cyclophosphamide, doxorubicin, cisplatin and megesterol producing the greatest response rate. Additionally, Pinelli et al. reported a 56% complete or partial response rate in a group of patients treated with carboplatin and sequential hormonal therapy with megesterol and tamoxifen. These studies suggest that sequential administration of hormonal therapy with chemotherapy has no detrimental effects on patients, and may be beneficial as hormonal therapy is generally less toxic than chemotherapy. Based on known tolerability and efficacy, investigating the combination of megesterol acetate with paclitaxel and carboplatin chemotherapy appears to be a reasonable option in the setting of advanced or recurrent endometrial cancer.
Accordingly, this phase II study will evaluate the combination of paclitaxel, carboplatin and megesterol acetate for the treatment of advanced or recurrent adenocarcinoma of the endometrium.
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| UAB 0403 | OTHER | University of Alabama at Birmingham | View |